Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib for conversion therapy in unresectable dMMR gastric cancer
ChiCTR2500100982Phase 2Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Peking University Third Hospital. Primary endpoint: 1-year progression-free survival rate. Started Apr 2025; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500100982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100982.